JRC Publications Repository

JRC Publications Repository >

Browsing by Author BRUCHERTSEIFER Frank

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:   
Sort by: In order: Results/Page Authors/Record:
Showing results 72 to 91 of 92
Publication YearTitleAuthor(s), Editor(s), Other Contributor(s)Publication Type
2009Spectroscopic Study of the Interaction of U(VI) with Transferrin and Albumin for Speciation of U(VI) under Blood Serum ConditionsMONTAVON Gilles; APOSTOLIDIS Christos; BRUCHERTSEIFER Frank; REPINC Urska; MORGENSTERN AlfredArticles in Journals
2014Step forward with Bi-213: Cyclen-based phosphonates show improved radiolabeling and stabilityŠIMEČEK Jakub; HERMANN Petr; SEIDL C.; MORGENSTERN Alfred; NOTNI Johannes; BRUCHERTSEIFER Frank; WESTER Hans-JürgenContributions to Conferences
2013Substance P - nanozeolite labeled with 224Ra and 225Ra - new potential radiobioconjugate for internal alpha therapyLESZCZUK Edyta; PIOTROWSKA A; KOŹMIŃSKI P; BILEWICZ Aleksander; MORGENSTERN Alfred; BRUCHERTSEIFER FrankContributions to Conferences
2012Synthesis and in vitro evaluation of 225Ac-DOTA-SubstanceP for targeted alpha therapy of glioblastoma multiformeMAJKOWSKA AGNIESZKA; BRUCHERTSEIFER Frank; WEIS Mirjam; BONELLI Milton; LAURENZA M; APOSTOLIDIS Christos; MORGENSTERN AlfredContributions to Conferences
2013Synthesis of 213Bi-DOTATOC for peptide receptor a-therapy of GEP-NET patients refractory to β-therapyBRUCHERTSEIFER Frank; MORGENSTERN Alfred; APOSTOLIDIS Christos; GIESEL Frederik; MIER Walter; HABERKORN Uwe; KRATOCHWIL ClemensContributions to Conferences
2012Synthesis of 213Bi-DOTATOC for peptide receptor alpha-therapy of GEP-NET patients refractory to beta therapyMORGENSTERN Alfred; BRUCHERTSEIFER Frank; APOSTOLIDIS Christos; GIESEL Frederik; MIER Walter; HABERKORN Uwe; KRATOCHWIL ClemensContributions to Conferences
2013Targeted alpha therapy of glioblastoma multiforme with 213Bi-substance PMORGENSTERN Alfred; KROLICKI Leszek; KUNIKOWSKA Jolanta; KOCIARA Henryk; KROLICKI B; JAKUCINSKI M; MIKOŁAJCZAK Renata; PAWLAK Dariusz; APOSTOLIDIS Christos; BRUCHERTSEIFER FrankContributions to Conferences
2013Targeted alpha therapy of glioblastoma multiforme: initial clinical experience with 213Bi-substance PMORGENSTERN Alfred; KROLICKI Leszek; KUNIKOWSKA Jolanta; KOZIARA H; KROLICKI B; JAKUCINSKI M; MIKOŁAJCZAK Renata; PAWLAK Dariusz; APOSTOLIDIS Christos; BRUCHERTSEIFER FrankContributions to Conferences
2011Targeted alpha therapy with 213BiMORGENSTERN Alfred; BRUCHERTSEIFER Frank; APOSTOLIDIS ChristosArticles in Journals
2010Targeted Alpha-Radionuclide Therapy of Functionally Critical Located Gliomas with 213Bismuth-DOTA-[Thi8,Met(O2)11]-Substance P - A Pilot TrialCORDIER D.; FORRER F.; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; APOSTOLIDIS Christos; GOOD S.; MÜLLER-BRAND J.; MÄCKE H.; REUBI Jean-Claude; MERLO A.Articles in Journals
2013Targeting aberrant DNA double strand break repair in triple negative breast cancer with alpha particle emitter radiolabeled anti-EGFR antibodySONG H.; HOBBS Robert F.; SHAO Chunbo; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; DEWEESE Tl; SGOUROS G.; HEDAYATI MohammadArticles in Journals
2012Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosisESSLER M.; GAERTNER F. C.; NEFF Frauke; BLECHERT B.; SENEKOWITSCH-SCHMIDTKE R.; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; SEIDL C.Articles in Journals
2009Therapeutic efficacy of intravesical -radioimmunotherapy with Bi-213-anti-EGFR-MAb in a human bladder cancer nude mouse modelPFOST B.; SEIDL C.; AUTENRIETH M.; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; SENEKOWITSCH-SCHMIDTKE R.Contributions to Conferences
2013TiO2 nanoparticles as carries of 225Ac/213Bi in vivo generatorsLESZCZUK Edyta; PIOTROWSKA A; BILEWICZ Aleksander; MORGENSTERN Alfred; BRUCHERTSEIFER FrankContributions to Conferences
2013TiO2 nanoparticles as carries of 225Ac/213Bi in vivo generatorLESZCZUK Edyta; PIOTROWSKA A; BILEWICZ Aleksander; MORGENSTERN Alfred; BRUCHERTSEIFER FrankContributions to Conferences
2012Towards developing a universal treatment for fungal disease using radioimmunotherapy targeting common fungal antigensBRYAN R. A.; GUIMARAES A.j.; HOPCRAFT S.; JIANG Z.; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; DEL POETA M.; TOTOSANTUCCI A.; CASSONE A.; NOSANCHUK J.d., et alArticles in Journals
2014Treatment of bladder cancer with Bi-213-anti-EGFR-MAb – a pilot studySCHEIDHAUER Klemens; SEIDL C.; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; APOSTOLIDIS Christos; AUTENRIETH Michael; KURTZ F; ESSLER M.; SCHWAIGER M.; SENEKOWITSCH-SCHMIDTKE R.Contributions to Conferences
2012Treatment of early and established Cryptococcus neoformans infection with radiolabeled antibodies in immunocompetent miceJIANG Z.; BRYAN R. A.; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; Casadevall Arturo; DADACHOVA E.Articles in Journals
2013Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA in combination with cisplatin and gemcitabineBRYAN R. A.; JIANG Z.; JANDL T; STRAUSS J; KOBA W; ONYEDIKA C; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; SELLERS R.; EPSTEIN A, et alContributions to Conferences
2009Treatment of Peritoneal Carcinomatosis by Targeted Delivery of the Radio-Labeled Tumor Homing Peptide 213Bi-DTPA-[F3]2 into the Nucleus of Tumor CellsDRECOLL E.; GAERTNER F. C.; MIEDERER M.; BLECHERT B.; VALLON M.; MÜLLER J.; ALKE A.; SEIDL C.; BRUCHERTSEIFER Frank; MORGENSTERN Alfred, et alArticles in Journals
Showing results 72 to 91 of 92

 

The mission of the JRC is to provide customer-driven scientific and technical support for the conception, development, implementation and monitoring of EU policies. As a service of the European Commission, the JRC functions as a reference centre of science and technology for the Union. Close to the policy-making process, it serves the common interest of the Member States, while being independent of special interests, whether private or national.
Powered by DSpace
Top